> Research Use Only (RUO) Disclaimer: 5-Amino-1MQ (5-amino-1-methylquinolinium) is an investigational small molecule used exclusively in preclinical and laboratory research settings. It has not been approved by the FDA or any regulatory authority for human use, therapeutic applications, or diagnostic purposes. The dosage parameters and protocols described in this guide are derived from published scientific literature on animal and in vitro studies. This content is provided for educational and research reference purposes only and does not constitute medical advice. Researchers must comply with all applicable local, state, and federal regulations governing research compound use.
---
What Is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule and selective inhibitor of nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme involved in nicotinamide metabolism and epigenetic regulation. Unlike conventional peptides that target extracellular receptors, 5-Amino-1MQ exerts its activity intracellularly — blocking NNMT to redirect metabolic flux and alter energy homeostasis in adipose tissue and the liver.
The compound emerged from the methylquinolinium inhibitor program at the University of Texas Medical Branch (UTMB) Galveston and UT San Antonio, with later development through Ridgeline Therapeutics. Research interest grew substantially following a landmark 2014 Nature Communications study (Kraus et al.) that demonstrated significant metabolic effects from NNMT inhibition in mouse adipose tissue.
5-Amino-1MQ is notable on the peptide marketplace for being primarily available as oral capsules or powder rather than as an injectable lyophilized vial — though injectable (subcutaneous) vial formats also exist. This distinction affects reconstitution and administration protocols covered in this guide.
For a comprehensive overview of 5-Amino-1MQ's biological profile and mechanistic research, see our 5-Amino-1MQ NNMT Inhibitor Research Profile.
---
Research Background: NNMT Inhibition Mechanism
Understanding the pharmacological basis of 5-Amino-1MQ requires understanding what NNMT does and why inhibiting it has metabolic consequences.
The NNMT Enzyme and Its Role
NNMT catalyzes the methylation of nicotinamide (vitamin B3) to 1-methylnicotinamide (1-MNA), consuming both nicotinamide and the universal methyl donor S-adenosylmethionine (SAM) in the reaction. This seemingly minor enzymatic step has two major downstream consequences that motivate research interest:
1. NAD⁺ precursor depletion: Nicotinamide is the primary substrate for the NAMPT-mediated salvage pathway that regenerates NAD⁺. When NNMT is overactive, it diverts nicotinamide away from this pathway, reducing intracellular NAD⁺ availability.
2. SAM depletion and epigenetic effects: SAM serves as the methyl donor for histone methyltransferases. NNMT over-consumption of SAM reduces histone H3K4 methylation — an active transcription mark — epigenetically suppressing metabolically favorable gene expression in adipose tissue. This is the NNMT-SAM-epigenome axis now recognized as a mechanism by which obesity perpetuates itself through epigenetic programming.
How 5-Amino-1MQ Acts
By selectively blocking NNMT, 5-Amino-1MQ produces a coordinated metabolic shift:
- •Raises intracellular NAD⁺ — more nicotinamide is redirected to the NAMPT salvage pathway, supporting mitochondrial oxidative phosphorylation, SIRT1/SIRT3 sirtuin activation, and ATP production
- •Restores SAM pools — less methyl donor is consumed by NNMT, restoring histone methylation patterns that favor metabolically active gene expression
- •Alters adipocyte phenotype — preclinical data show a shift from energy-storing white adipocyte behavior toward increased fatty acid oxidation and reduced lipid accumulation in differentiating fat cells
- •Reduces 1-MNA production — lower 1-MNA levels reflect direct NNMT inhibition and serve as a measurable endpoint in research studies
Key Preclinical Findings
- •In diet-induced obese mice, subcutaneous 5-Amino-1MQ (~34 mg/kg/day for 11 days) reduced body weight, total fat mass, and plasma cholesterol without altering food intake or lean mass
- •A 28-day follow-up study (Babula et al., 2024) confirmed dose-dependent attenuation of body weight and fat mass gain in obese mice, with improved liver markers, again without affecting food consumption
- •Elevated NNMT activity is documented in the liver and white adipose tissue of obese and diabetic animal models — supporting the mechanistic rationale for NNMT inhibition as a metabolic intervention target
NNMT inhibition and NAD⁺ precursor supplementation operate on adjacent — but distinct — nodes of the same metabolic network. See our NAD⁺ Dosage Protocol Guide for protocols targeting the complementary NAD⁺ axis directly.
---
5-Amino-1MQ Formats: Oral vs. Injectable
Unlike most compounds on the peptide marketplace, 5-Amino-1MQ is commonly available in two distinct formats with different reconstitution requirements:
| Format | Administration | Typical Concentration | Notes |
|---|---|---|---|
| Oral capsules / powder | Swallowed | 50–150 mg per capsule | Most common format; no reconstitution needed |
| Lyophilized vial | Subcutaneous injection | 10 mg or 50 mg vials | Requires reconstitution with bacteriostatic water |
The oral format is far more prevalent in research supplier catalogs. The subcutaneous injectable format is available from some suppliers but is less common for this particular compound.
---
Reconstitution Guide (Injectable Vial Format)
This section applies only to lyophilized vial presentations. If working with oral capsules or powder, skip to Research Dosing Protocols.
Equipment Required
- •Lyophilized 5-Amino-1MQ vial (10 mg or 50 mg)
- •Bacteriostatic water for injection (BAC water)
- •Insulin syringes (1 mL, 27–31 gauge)
- •Alcohol swabs
- •Sterile technique
Reconstitution Steps
Step 1 — Prepare surfaces and hands. Swab the vial stopper with an alcohol wipe and allow to fully dry (10–15 seconds).
Step 2 — Draw bacteriostatic water. Using an insulin syringe, draw the appropriate volume of BAC water:
- •10 mg vial: Add 2.0 mL BAC water → yields 5 mg/mL concentration
- •50 mg vial: Add 5.0 mL BAC water → yields 10 mg/mL concentration
These concentrations allow accurate dosing with standard insulin syringes.
Step 3 — Inject at an angle. Insert the needle at a 45-degree angle through the rubber stopper. Aim the stream of water toward the inner glass wall — never directly onto the lyophilized powder cake, as this can degrade the compound.
Step 4 — Allow passive dissolution. Let the vial sit undisturbed for 1–2 minutes. If powder remains visible, gently swirl (do not shake). The solution should become clear.
Step 5 — Label and store. Write the reconstitution date on the vial. Reconstituted 5-Amino-1MQ should be refrigerated at 2–8°C and used within 28 days.
---
Research Dosing Protocols
All dosage parameters below are derived from preclinical animal research, in vitro studies, and research community protocols. No human clinical trials have established safety or efficacy for 5-Amino-1MQ in any context.
Oral Protocol (Capsule / Powder)
Standard Research Protocol:
| Phase | Daily Dose | Duration | Notes |
|---|---|---|---|
| Titration | 50 mg once daily (morning) | Weeks 1–2 | Assess baseline response |
| Maintenance | 100 mg once daily | Weeks 3–8 | Standard research dose |
| Extended maintenance | 100–150 mg/day (split dose or once daily) | Weeks 9–12 | Upper range for extended studies |
Typical research cycle: 8–12 weeks on, followed by 4–6 weeks off before restarting. The off-period allows NNMT baseline activity to normalize before the next research cycle.
Timing: Morning administration (fasted or with light meal) is most commonly used in research protocols. Some researchers split the dose (e.g., 50 mg morning + 50 mg afternoon) to maintain steadier compound exposure.
Subcutaneous Injectable Protocol (Vial Format)
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Start | 2.5 mg | Once daily | Tolerance assessment |
| Standard | 5 mg | Once daily | Typical research target |
| Advanced | 2.5 mg × 2 | Twice daily (BID) | Alternative to single 5 mg dose |
Injection site: Rotate among abdominal subcutaneous sites, outer thigh, or lateral upper arm. Allow 2-inch separation between injection sites.
Stacking with NAD⁺ Precursors
Research interest has grown around combining 5-Amino-1MQ with NAD⁺ precursors such as NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside). The rationale: 5-Amino-1MQ frees up nicotinamide for the NAMPT salvage pathway, while exogenous NMN/NR provides additional substrate for NAD⁺ synthesis — the two operate on adjacent but complementary nodes of the same pathway.
No published study has evaluated this combination in a controlled research design; synergy remains hypothetical at this stage. Researchers working on the NAD⁺ axis may reference our NAD⁺ vs NMN Longevity Compound Comparison for further context.
---
Administration Notes
Oral Administration (Capsule / Powder)
- •Take with water; food intake at dosing time has not been systematically compared in research protocols
- •Maintain consistent dosing time for intra-study consistency
- •If using bulk powder rather than capsules, use an accurate milligram-capable scale (0.001 g resolution)
- •Oral bioavailability data for 5-Amino-1MQ in humans is not established; preclinical pharmacokinetic characterization has been primarily conducted in rodent models
Subcutaneous Administration (Injectable)
- •Use a fresh, sterile insulin syringe for each injection
- •Swab injection site with alcohol wipe; allow to dry fully before injecting
- •Inject at a 45-degree angle into the subcutaneous fat layer; withdraw needle smoothly
- •Rotate injection sites to prevent localized tissue response
- •Discard any unused reconstituted solution after 28 days regardless of visual appearance
---
Storage and Stability
| Form | Storage Condition | Stability |
|---|---|---|
| Lyophilized powder (vial, sealed) | −20°C (frozen) | Up to 24 months |
| Lyophilized powder (vial, refrigerated) | 2–8°C | Up to 3 months |
| Reconstituted solution (injectable) | 2–8°C | 28 days |
| Oral capsules / sealed powder | Cool, dry, dark storage | Per supplier specification |
Key storage principles:
- •Protect lyophilized vials from repeated freeze-thaw cycles; once thawed for reconstitution, do not refreeze
- •Avoid prolonged room-temperature exposure — even for brief periods during handling
- •Once opened, oral powder should be stored in an airtight container away from humidity and light
- •Inspect reconstituted solutions before each use; discard if cloudy, discolored, or particulate matter is visible
---
Safety Considerations in Research
5-Amino-1MQ has not been evaluated for safety in human clinical trials. The following considerations apply to preclinical research design:
Preclinical safety profile:
- •In 11-day and 28-day rodent studies, no overt signs of toxicity were reported at research doses (~34 mg/kg/day subcutaneous in mice)
- •No effects on food intake or lean mass were observed in published animal studies
- •Liver marker improvements were noted in the 28-day study — an encouraging signal in the context of metabolic disease research, but insufficient to characterize human hepatic safety
Unknown factors:
- •Long-term safety data (beyond 28 days) in animal models is limited
- •Human pharmacokinetics, bioavailability, and metabolism have not been characterized
- •Drug interaction profile with common medications is unknown
- •Purity and GMP-manufacturing status of research-grade suppliers varies; independent testing of compound identity and purity is advised for rigorous research protocols
Contraindications in research design:
- •Research designs should account for NNMT's roles beyond fat metabolism — including serotonin degradation (NNMT is involved in tryptophan/serotonin catabolism) and potential interactions in liver disease models where NNMT expression is altered
- •Studies involving subjects with pre-existing metabolic syndrome, liver conditions, or NAD⁺ pathway modifications should note these as potential confounders
---
Compound Summary
| Parameter | Details |
|---|---|
| Compound class | Methylquinolinium small molecule (not a peptide) |
| Primary mechanism | NNMT inhibition → NAD⁺ precursor preservation + SAM conservation |
| Research formats | Oral capsules/powder; lyophilized subcutaneous vials |
| Typical research doses | Oral: 50–150 mg/day; Injectable: 2.5–5 mg/day |
| Cycle length | 8–12 weeks on, 4–6 weeks off (research community standard) |
| Regulatory status | Research chemical; no FDA approval for human use |
| Primary research areas | Metabolic syndrome, obesity, fatty liver, NAD⁺ biology, aging |
---
Frequently Asked Questions
Is 5-Amino-1MQ a peptide?
No. 5-Amino-1MQ is a synthetic small molecule — specifically a methylquinolinium quaternary ammonium salt — not a peptide. It is commonly catalogued alongside peptides on research supplier platforms due to overlapping research interest areas, but its structure and mechanism differ fundamentally from peptide compounds.
Why does 5-Amino-1MQ come as capsules rather than injectables?
5-Amino-1MQ is a small molecule with oral activity, unlike many peptide research compounds that are degraded in the GI tract and require subcutaneous administration. Oral availability makes capsule or powder formats practical for research. Injectable vials are available from some suppliers for researchers preferring that delivery route.
Can 5-Amino-1MQ and NMN be combined in research protocols?
Research interest in this combination exists due to the complementary mechanisms — NNMT inhibition preserves nicotinamide for the salvage pathway while NMN provides direct substrate. No published study has evaluated the combination in a controlled research design; synergy remains hypothetical at this stage.
How does 5-Amino-1MQ differ from NNMT siRNA or genetic knockdown models?
Pharmacological inhibition via 5-Amino-1MQ is reversible and titratable, making it more suitable for temporal intervention studies. Genetic knockdown models (siRNA, knockout) are constitutive and harder to dose-control. 5-Amino-1MQ also allows tissue-selective delivery in some experimental designs.
---
> Research Use Only: This article is for educational and research purposes only. 5-Amino-1MQ has not been approved by the FDA or any regulatory authority for human use. For research purposes only. Not for human consumption. This information is for educational and research use only. Always consult current peer-reviewed literature and relevant institutional guidelines when designing research protocols.